Nanobiotix S.A.
NBTX
$51.50
-$3.57-6.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.76M | 20.55M | 8.02M | -2.81M | -12.58M |
| Total Other Revenue | 3.32M | 3.28M | 3.27M | 3.98M | 4.78M |
| Total Revenue | 36.08M | 23.83M | 11.29M | 1.17M | -7.80M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 36.08M | 23.83M | 11.29M | 1.17M | -7.80M |
| SG&A Expenses | 22.93M | 22.83M | 22.86M | 22.28M | 22.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.83M | 53.62M | 58.84M | 61.84M | 66.06M |
| Operating Income | -12.75M | -29.79M | -47.55M | -60.67M | -73.86M |
| Income Before Tax | -27.56M | -41.42M | -56.01M | -64.65M | -73.62M |
| Income Tax Expenses | 3.10K | -18.10K | -39.90K | 34.20K | 109.20K |
| Earnings from Continuing Operations | -27.56 | -41.40 | -55.97 | -64.69 | -73.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.56M | -41.40M | -55.97M | -64.69M | -73.73M |
| EBIT | -12.75M | -29.79M | -47.55M | -60.67M | -73.86M |
| EBITDA | -12.32M | -29.26M | -46.92M | -59.77M | -72.68M |
| EPS Basic | -0.57 | -0.87 | -1.18 | -1.37 | -1.56 |
| Normalized Basic EPS | -0.35 | -0.55 | -0.75 | -0.88 | -1.01 |
| EPS Diluted | -0.58 | -0.87 | -1.18 | -1.37 | -1.56 |
| Normalized Diluted EPS | -0.35 | -0.55 | -0.75 | -0.88 | -1.01 |
| Average Basic Shares Outstanding | 191.28M | 190.46M | 189.65M | 189.35M | 189.06M |
| Average Diluted Shares Outstanding | 191.28M | 190.46M | 189.65M | 189.35M | 189.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |